Meta-analysis for Qishen Yiqi Dropping Pills in Treatment of Chronic Heart Failure with Syndrome of Qi Deficiency and Blood Stasis

Yi-li ZHANG; Juan WANG; Yuan LI; Hui-hui ZHAO; Jun-jie LIU; Wei WANG

doi:10.13422/j.cnki.syfjx.20191447

您当前的位置：

首页 >

文章列表页 >

Meta-analysis for Qishen Yiqi Dropping Pills in Treatment of Chronic Heart Failure with Syndrome of Qi Deficiency and Blood Stasis

Data Mining | 更新时间：2021-02-09

- Meta-analysis for Qishen Yiqi Dropping Pills in Treatment of Chronic Heart Failure with Syndrome of Qi Deficiency and Blood Stasis
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 25, Issue 21, Pages: 162-169(2019)
- 作者机构：
  
  1.北京中医药大学，证候与方剂基础研究北京市重点实验室，证候与方剂基础研究教育部重点实验室，北京　 100029；
  2.北京中医药大学　东直门医院，北京　 100700
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20191447
  CLC： R22; R24; R4; C37; R541.6
- Published：05 November 2019，
  
  Published Online：01 April 2019，
  
  Received：25 December 2018，
- 稿件说明：
扫描看全文
Yi-li ZHANG, Juan WANG, Yuan LI, et al. Meta-analysis for Qishen Yiqi Dropping Pills in Treatment of Chronic Heart Failure with Syndrome of Qi Deficiency and Blood Stasis. [J]. Chinese Journal of Experimental Traditional Medical Formulae 25(21):162-169(2019)
DOI：

Yi-li ZHANG, Juan WANG, Yuan LI, et al. Meta-analysis for Qishen Yiqi Dropping Pills in Treatment of Chronic Heart Failure with Syndrome of Qi Deficiency and Blood Stasis. [J]. Chinese Journal of Experimental Traditional Medical Formulae 25(21):162-169(2019) DOI： 10.13422/j.cnki.syfjx.20191447.

摘要

目的：

评价芪参益气滴丸治疗慢性心力衰竭的有效性及安全性。

方法：

计算机检索国内外8个数据库，筛选芪参益气滴丸治疗慢性心力衰竭的随机对照试验；运用Cochrane协作网偏倚风险评价工具对纳入研究进行文献质量评价，利用RevMan 5.3软件进行Meta分析。

结果：

检索相关文献606篇，最终纳入11项研究，涉及931例患者，纳入文献质量普遍偏低。Meta分析结果显示，芪参益气滴丸联合常规西药在改善B型利钠肽[加权均数差(WMD)＝－29.47，95%置信区间(CI)(－37.29，－21.64)，

0.000 01]，左心室射血分数[WMD＝4.64，95%CI(3.82，5.47)，

0.000 01]，心功能分级疗效[相对危险度(RR)＝1.25，95%CI(1.16，1.35)，

0.000 01]，中医证候疗效[RR＝1.23，95%CI(1.07，1.43)，

＝0.005]，6分钟步行试验[WMD＝50.13，95%CI(22.32，77.93)，

＝0.000 4]指标方面，疗效均优于单用常规西药。安全性指标方面，1篇研究拟观察安全性指标，但实际文献中并未报告，其余研究均未发现芪参益气滴丸联合常规西药治疗的不良反应。

结论：

该研究结果支持临床使用芪参益气滴丸联合常规西药治疗慢性心力衰竭，但鉴于纳入临床研究在数量及质量上存在一定局限性，得出的阳性结果仅作为临床诊疗的提示与参考，还需更多高质量的研究进一步证实其疗效。

Abstract

Objective:

To evaluate the efficacy and safety of Qishen Yiqi dropping pills in the treatment of chronic heart failure.

Method:

Eight databases were searched at home and abroad

and the randomized controlled trials of Qishen Yiqi dropping pills in the treatment of chronic heart failure were screened. Literature quality of the included studies was evaluated by the bias risk assessment tool of Cochrane collaboration network

and the Meta-analysis was performed by RevMan 5.3 software.

Result:

A total of 606 related literature were retrieved

and 11 studies were eventually included

involving 931 patients. The quality of the included literature was generally low. Meta-analysis results showed that efficacy of Qishen Yiqi dropping pills combined with conventional western medicine was better than conventional western medicine alone in improving B-type natriuretic peptide [weighted mean difference (WMD)=-29.47

95%confidence interval (CI) (-37.29

-21.64)

0.000 01]

left ventricular ejection fraction [WMD=4.64

95%CI (3.82

5.47)

0.000 01]

cardiac function classification efficacy [relative risk (RR)=1.25

95%CI (1.16

1.35)

0.000 01]

therapeutic effect of traditional Chinese medicine syndrome [RR=1.23

95%CI (1.07

1.43)

=0.005]

6-minute walk test [WMD=50.13

95%CI (22.32

77.93)

=0.000 4]. In terms of safety indicators

one study intended to observe safety indicators

but it was not reported in the actual literature

and the remaining studies did not find adverse reactions of Qishen Yiqi dropping pills combined with conventional western medicine.

Conclusion:

The results of this study support the clinical use of Qishen Yiqi dropping pills combined with conventional western medicine in the treatment of chronic heart failure

but in view of the limitations in the quantity and quality of clinical studies

the positive results are only used as a reminder and reference for clinical diagnosis and treatment. In the future

more high-quality researches are needed to further confirm its efficacy.

关键词

芪参益气滴丸心力衰竭气虚血瘀系统评价安慰剂常规西药治疗不良反应

Keywords

Qishen Yiqi dropping pillsheart failureQi deficiency and blood stasissystematic reviewplaceboconventional western medicine treatmentadverse reactions

references

中华医学会心血管病学分会心力衰竭学组．中国心力衰竭诊断和治疗指南2018[J]．中华心血管病杂志，2018，46(10)：760-789．

Mosterd A, Hoes A W. Clinical epidemiology of heart failure [J].Heart, 2007, 93(9): 1137-1146.

ZHANG Y H, ZHANG J, Butler J, et al. Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in China: Results from the China heart failure (China-HF) registry [J].J Card Fail, 2017, 23(12): 868-875.

冠心病中医临床研究联盟．慢性心力衰竭中医诊疗专家共识[J]．中医杂志，2014，55(14)：1258-1261．

中国中西医结合学会心血管疾病专业委员会．慢性心力衰竭中西医结合诊疗专家共识[J]．中国中西医结合杂志，2016，36(2)：133-142．

胡婷，包怡敏．益气活血法抗心肌缺血再灌注损伤的作用机制[J]．中国实验方剂学杂志，2018，24(22)：228-234．

赵桂峰，吴丽玉，许传嘉．芪参益气滴丸对心梗后大鼠心功能及心肌纤维化相关蛋白表达的影响[J]．中国实验方剂学杂志，2018，24(4)：131-136．

田野，顾健霞．芪参益气滴丸治疗冠心病心力衰竭的Meta分析[J]．中国中医急症，2016，25(9)：1725-1729．

刘军刚，顾万红，刘效栓，等．芪参益气滴丸治疗慢性心力衰竭的Meta分析[J]．中国新药与临床杂志，2014，33(3)：189-196．

张彬．芪参益气滴丸治疗气虚血瘀型慢性心衰的临床观察[D]．沈阳：辽宁中医药大学，2013．

吴邵红．芪参益气滴丸对慢性充血性心力衰竭患者中医症候和心功能的影响[J]．中国药物经济学，2014，9(S1)：62-63．

孙艳玲．芪参益气滴丸治疗慢性心力衰竭60例临床观察[J]．湖南中医杂志，2014，30(12)：45-47．

丁树根，周明林，郑梅生．芪参益气滴丸治疗慢性心力衰竭的临床疗效观察[J]．光明中医，2014，29(2)：293-294．

林国伟．芪参益气滴丸治疗气虚血瘀型心力衰竭临床研究[D]．广州：广州中医药大学，2014．

杨国栋．芪参益气滴丸治疗慢性充血性心力衰竭临床分析[J]．亚太传统医药，2015，11(7)：114-115．

马春亚．芪参益气滴丸治疗气虚血瘀型慢性心力衰竭的临床疗效观察[J]．医药前沿，2015，5(36)：347-348．

项素珍．芪参益气滴丸治疗气虚血瘀型慢性心衰(冠心病心功能不全)的临床观察[D]．武汉：湖北中医药大学，2015．

陈晖．芪参益气滴丸治疗气虚血瘀型射血分数降低性心力衰竭临床观察[J]．承德医学院学报，2016，33(5)：396-398．

魏瑜，赵珍．芪参益气滴丸治疗气虚血瘀型慢性心衰的疗效观察[J]．医药前沿，2017，7(18)：361-362．

胡军．探讨芪参益气滴丸对冠心病慢性心力衰竭(气虚血瘀证)患者心率变异性(HRV)的影响[D]．成都：成都中医药大学，2017．

张玲．芪参益气方促血管新生机制及抗心肌缺血作用研究[D]．杭州：浙江大学，2011．

Kajdaniuk D, Marek B, Borgiel-Marek H, et al. Vascular endothelial growth factor(VEGF)-part 1: in physiology and pathophysiology [J].Endokrynol Pol, 2011, 62(5): 444-455.

李彦川，刘育英，陈媛媛，等．芪参益气滴丸后给药对心肌肥厚大鼠心肌纤维化的阻断作用[C]//中国中西医结合学会．第十次中国中西医结合微循环学术会议论文集：2010年卷．厦门：出版社不详，2010：67．

WANG Y, WANG J, GUO L P, et al. Antiplatelet effects of qishen yiqi dropping pill in platelets aggregation in hyperlipidemic rabbits [J].Evid Based Complement Alternat Med, 2012, doi: 10.1155/2012/205451http://doi.org/10.1155/2012/205451.

LIN S Q, WEI X H, HUANG P, et al. QiShenYiQi Pills® prevents cardiac is chemia-reperfusion injury via energy modulation [J].Int J Cardiol, 2013, 168(2): 967-974.

朱明丹，杜武勋，刘长玉，等．芪参益气滴丸对AMI大鼠心肌炎症因子影响的动态观察[J]．时珍国医国药，2013，24(1)：22-24．

崔佩佩，王刚，宋生有，等．芪参益气滴丸对大鼠心肌缺血Ppp3r1及Atp5d基因表达变化的影响[J]．药物评价研究，2010，33(3)：191-193．

郝海群．缺血性心力衰竭采用芪参益气滴丸治疗的有效性和安全性分析[J]．中医临床研究，2015，7(22)：74-75．

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of Medication Rules of Coronary Heart Disease with Heart Failure of Qi Deficiency and Blood Stasis Syndrome Based on Literature Research

Qishen Yiqi Dropping Pills for Ischemic Heart Failure：A Systematic Review

Systematic Review of Yiqi Fumai Injection for Patients with Heart Failure

Roles of Aquaporins in Cardiovascular Diseases and Traditional Chinese Medicine Intervention： A Review

Astragali Radix-Curcumae Rhizoma Inhibits Metastasis of Lewis Lung Cancer in Mice via C5a/NETs Pathway

Related Author

Li-jie QIAO

Guang-cao PENG

Jing-jing WEI

Teng MA

Bin LI

Rui YU

Yong-xia WANG

Ming-jun ZHU

Related Institution

The First Clinical Medical College， Henan University of Chinese Medicine

The First Affiliated Hospital of Henan University of Chinese Medicine

Liaoning University of Traditional Chinese Medicine（TCM）

The Affiliated Hospital of Liaoning University of TCM

Chinese PLA Medical School

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰